Tag Archive for: Investors

Sector updates in April

/in

  Investment firms  Jeito Capital raised a record $1.2 billion for Jeito II Fund to support clinical stage biopharma companies developing breakthrough therapies for diseases with high unmet medical needs  Kurma Partners raised €215 million for Biofund IV to support the discovery and development of disruptive therapeutic solutions for severe or incurable diseases  British Business Bank made a £100 million cornerstone commitment to Apposite Healthcare Growth Fund I to support innovative companies across medical products, diagnostics, life science tools, digital health and […]

Read more

Register today: Anglonordic Life Science Conference 2026

/in

As one of the organisers, Optimum is proud to partner with Anglonordic year on year to curate an awesome agenda for this fantastic event. Exclusively for European investors and R&D companies…

Read more

Hot topic: JPM 2026 – Deal or no deal – and does it matter?

/in

JPM 2026 was touted as the event that would usher in the best year in biotech in a long time.  But when it happened there was a distinct lack of mega-deals to shout about.  The elephant, you might say, was not in the room.  Does this bode ill for 2026? Or is news of such […]

Read more

Resolution Therapeutics to Host Virtual Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.

/in

Highlighting Clinical Data and Discovery Platform Following Presentations at EASL Congress 2024 Edinburgh and London, UK, 13 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease, today announces that it will host a virtual R&D webinar on Friday 28th June 2024 at 12.30 BST / 7.30 […]

Read more

Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference

/in

Edinburgh and London, UK, 28 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering engineered autologous macrophage cell therapies to transform the treatment of inflammatory organ diseases, today announced that Amir Hefni, Ph.D., Chief Executive Officer, and Simon Ramsden, Chief Financial Officer, will participate in meetings with investors at the […]

Read more